This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...

The World Health Organization (WHO) has officially announced that Burundi has eliminated trachoma as a public health problem, ...

The World Health Organization (WHO) has validated Senegal as having eliminated trachoma as a public health problem. Senegal ...

The World Health Organization (WHO) has validated Burundi as having eliminated trachoma as a public health problem, making it the eighth country in WHO’s African Region to reach this important ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Planned Parenthood has won a partial victory in a legal fight with President Donald Trump’s administration over its efforts ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.